These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1743623)
1. Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas. Fridrik MA; Hausmaninger H; Michlmayr G; Haidinger R; Seewann HL; Lehnert M Hematol Oncol; 1991; 9(4-5):209-15. PubMed ID: 1743623 [TBL] [Abstract][Full Text] [Related]
2. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202 [TBL] [Abstract][Full Text] [Related]
3. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy. Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in patients with acquired immunodeficiency virus syndrome associated with non-Hodgkin's lymphoma. Fridrik MA; Geit M; Wahl G; Ehrengruber A; Simma R; Höpfel I; Bettelheim P; Leisch F Wien Klin Wochenschr; 1998 Jan; 110(1):15-9. PubMed ID: 9499473 [TBL] [Abstract][Full Text] [Related]
5. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma. Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759 [TBL] [Abstract][Full Text] [Related]
6. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen. Herbrecht R; Ortiz S; Damonte JC; Liu KL; Maloisel F; Dufour P; Bergerat JP; Oberling F Hematol Oncol; 1991; 9(4-5):253-7. PubMed ID: 1720760 [TBL] [Abstract][Full Text] [Related]
7. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793 [TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
9. Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study. Aurer I; Duraković N; Radman I; Nemet D; Zupancić-Salek S; Kovacević-Metelko J; Bogdanić V; Sertić D; Mrsić M; Mikulić M; Labar B Croat Med J; 2002 Oct; 43(5):550-4. PubMed ID: 12402394 [TBL] [Abstract][Full Text] [Related]
10. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma. De Lord C; Newland AC; Linch DC; Vaughan Hudson B; Vaughan Hudson G Hematol Oncol; 1992; 10(2):81-6. PubMed ID: 1592365 [TBL] [Abstract][Full Text] [Related]
11. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study. De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844 [TBL] [Abstract][Full Text] [Related]
13. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393 [TBL] [Abstract][Full Text] [Related]
14. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500 [TBL] [Abstract][Full Text] [Related]
15. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study. Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756 [TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744 [TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide. Sangster G; Patton WN; Harris RI; Grieve RJ; Leyland MJ Cancer Chemother Pharmacol; 1989; 23(4):263-5. PubMed ID: 2924382 [TBL] [Abstract][Full Text] [Related]